Literature DB >> 30900978

Suboptimal Handling of Piccolo Samples or Reagent Discs for Consideration in Ebola Response.

Jessica R Spengler, Stephen R Welch, Sarah C Genzer, JoAnn Coleman-McCray, Jessica R Harmon, Stuart T Nichol, Christina F Spiropoulou.   

Abstract

Operating clinical analyzers within recommended parameters can be challenging during outbreak response. Using the Piccolo Xpress point-of-care blood chemistry analyzer on guinea pig blood, we found that values of many analytes are still readily comparable when samples and reagent discs are handled at various conditions outside of manufacturer recommendations.

Entities:  

Keywords:  Ebola; Ebola virus disease; clinical chemistry; field studies; hemorrhagic fever; mobile treatment unit; outbreak response; point-of-care; viruses

Mesh:

Year:  2019        PMID: 30900978      PMCID: PMC6537746          DOI: 10.3201/eid2506.181928

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Blood chemistry analyses are useful for guiding patient care. However, following manufacturer-recommended handling and storage conditions can be challenging in areas with underdeveloped infrastructure, as experienced in past and ongoing Ebola outbreak response (). To investigate the utility of data from samples or reagent discs handled under suboptimal conditions, we evaluated 14 conditions outside of manufacturer recommendations by using Strain 13/N guinea pig blood and plasma samples. Animal procedures were approved by the Centers for Disease Control and Prevention Institutional Animal Care and Use Committee and conducted at an AAALAC-International–accredited facility. Samples were run on the Abaxis Piccolo Xpress Chemistry Analyzer (https://www.abaxis.com; quality control with Abbot General Chemistry controls and verification sample, https://www.fishersci.com/shop/products/pic-lpd-pls-gen-chm-ct-2x6x1ml/07p0401a). This platform is a compact and portable Clinical Laboratory Improvement Amendments–approved automated point-of-care system for whole blood, serum, and plasma (). This platform, together with the General Chemistry 13 reagent disc used here, is widely used in past and ongoing Ebola outbreak responses (–) and in laboratory research on viral pathogenesis, therapeutics, and vaccine efficacy (–). All samples were collected in the recommended lithium heparin (LiH) tubes, except as indicated. We determined intrinsic variation of each analyte under recommended conditions by running 31 samples on 2 different machines simultaneously or on 1 machine sequentially (represented as mean percentage change ± SD). We then evaluated 2 blood collection anticoagulants, 8 sample storage conditions, and 4 reagent disc storage conditions. Overall, >200 samples from 93 guinea pigs (48 males, 45 females; 7 were <1 month of age, 24 were 1–3 months, 8 were 4–6 months, 16 were 7–12 months, 17 were 1–2 years, 11 were 2–3 years, and 10 were >3 years), from healthy animals or animals with noninfectious chronic disease (e.g., renal failure) were analyzed. We first evaluated the effect of anticoagulants on sample analytes. Blood was collected and then partitioned from the syringe into paired samples stored in LiH (baseline), EDTA, or sodium citrate. Deviations from baseline were determined and expressed as mean percentage differences (Table; Appendix [expanded color version]). As expected, because of the chelating action of EDTA, assay reactions involving cationic substrates (Ca2+, alkaline phosphatase) generated no values or were greatly altered, although values of several analytes remained closely comparable to baseline. Values from samples collected in sodium citrate were uniformly lower than those collected in LiH.
Table

Mean percentage change of clinical chemistry values obtained on the Piccolo Xpress Chemistry Analyzer from blood samples or reagent discs processed under various conditions that deviated from the manufacturer’s recommendations*

Condition No. tested Percentage change compared with baseline
GLUBUNCRECAALBTPALTASTALPTBILGGTAMY
Sample collection













WB in EDTA†
15
−3.0
0.2
−0.8
ERR
4.1
−3.0
1.4
10.9
−93.2
−0.6
21.0
−1.7
WB in Na citrate†
18
−30.0
−23.3
−20.8
−59.1
−31.0
−34.4
−36.5
−23.6
−38.1
−6.9
−31.3
−0.5
Sample handling













WB 4°C O/N†
13
−19.2
1.2
−9.4
−1.0
−2.3
0.0
1.6
20.1
−2.5
−1.9
227.3
0.0
WB RT O/N†
16
−76.4
1.7
−4.7
2.0
−4.2
4.9
−0.1
37.7
−9.3
0.6
572.3
1.2
WB 32°C O/N†
16
−92.6
8.9
6.4
0.7
−4.1
6.3
−0.2
64.0
−10.5
−1.8
489.0
2.8
WB −20°C O/N†
3‡
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
PL†
35
−0.4
1.1
13.2
1.2
1.1
0.1
2.8
−1.5
2.1
4.7
−11.1
−0.1
PL RT O/N§
15
0.4
2.9
−11.3
0.3
−4.1
1.9
−0.4
1.8
−3.3
−4.8
1.5
−0.5
PL 32°C O/N§
18
0.2
6.1
−12.2
0.1
−6.2
2.2
−5.5
2.1
−0.6
3.9
0.2
−0.5
PL −20°C O/N§
14
−1.1
0.4
−3.9
−2.4
−0.6
−1.6
2.5
4.0
−5.9
−3.6
0.0
−0.5
PL −20°C O/N + 
 γ-irradiation§
16
0.3
3.4
11.3
2.5
0.0
−4.9
−12.3
−13.2
−15.8
1.6
−15.8
−0.5
Disc handling













WB + disc RT 7 d†
15
−3.4
1.1
−3.6
−1.4
0.9
0.6
3.0
2.2
−2.9
2.2
36.6
1.2
WB + disc 32°C 5 d†
12
−4.3
0.5
56.7
0.3
1.3
0.8
−4.1
1.8
7.6
−7.5
22.0
1.7
WB + disc 32°C 14 d†¶
7‡
−0.9
ERR
ERR
−1.8
−8.0
−0.5
5.3
−0.2
ERR
0.0
0.5
−0.5
WB + disc 32°C 5 wk†
2‡
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
ERR
Intrinsic variation













±1 SD

3.0
2.8
18.3
1.5
3.1
1.8
8.9
4.0
13.2
16.6
20.3
1.8
±2 SD

5.9
5.7
36.5
3.1
6.2
3.7
17.7
8.1
26.5
33.3
40.6
3.7
Reference values#143 ± 16
mg/dL20.5 ± 3.3 mg/dL0.32 ± 0.2 mg/dL11.4 ± 0.5 mg/dL2.9 ± 0.2
g/dL5.4 ± 0.3
g/dL27 ± 6
U/L46 ± 15
U/L43 ± 15
U/L0.3 ± 0.04 mg/dL10 ± 3
U/L1,149 ± 131 U/L

*All analytes were quantified with the Piccolo General Chemistry 13 reagent discs (https://www.abaxis.com). Baseline values were obtained from aliquots of the same samples run according to manufacturer’s recommendations for comparison. Values in white cells varied by <1 SD; values in light gray cells, by 1–2 SD; and values in dark gray cells, by >2 SD from the determined % intrinsic variation derived from analysis of samples run either sequentially on the same machine or in parallel on different machines. γ indicates γ-irradiated at 5 × 106 rads. ALB, albumin; AMY, amylase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CA, calcium; CRE, creatinine; ERR, analyte, sample, or disc error; GGT, γ-glutamyltransferase; GLU, glucose; Na, sodium; O/N, overnight; PL, plasma; RT, room temperature; TBIL, total bilirubin; TP, total protein; WB, whole blood. An expanded version of this table is available online (https://wwwnc.cdc.gov/EID/article/25/6/18-1928-T1.htm).
†Baseline sample: WB.
§‡Smaller sample size tested because tests did not function at indicated condition. 
‡§Baseline sample: PL.
¶Only subset of discs (7 of 10) generated values; remainder generated no values because of disc error.
#Reference values for strain 13/N guinea pigs 50–900 d of age, expressed as mean ± SD (10).

*All analytes were quantified with the Piccolo General Chemistry 13 reagent discs (https://www.abaxis.com). Baseline values were obtained from aliquots of the same samples run according to manufacturer’s recommendations for comparison. Values in white cells varied by <1 SD; values in light gray cells, by 1–2 SD; and values in dark gray cells, by >2 SD from the determined % intrinsic variation derived from analysis of samples run either sequentially on the same machine or in parallel on different machines. γ indicates γ-irradiated at 5 × 106 rads. ALB, albumin; AMY, amylase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CA, calcium; CRE, creatinine; ERR, analyte, sample, or disc error; GGT, γ-glutamyltransferase; GLU, glucose; Na, sodium; O/N, overnight; PL, plasma; RT, room temperature; TBIL, total bilirubin; TP, total protein; WB, whole blood. An expanded version of this table is available online (https://wwwnc.cdc.gov/EID/article/25/6/18-1928-T1.htm).
†Baseline sample: WB.
§‡Smaller sample size tested because tests did not function at indicated condition. 
‡§Baseline sample: PL.
¶Only subset of discs (7 of 10) generated values; remainder generated no values because of disc error.
#Reference values for strain 13/N guinea pigs 50–900 d of age, expressed as mean ± SD (10). To assess effects of sample storage temperatures on data output, we conducted similar analyses on whole blood stored overnight at −20°C, −4°C, or room temperature (≈20°C–22°C) and on plasma stored overnight at −20°C, room temperature, or 32°C. In general, plasma was more resistant to suboptimal temperatures; values for most analytes were comparable with paired control. Although data from whole blood samples varied more, many analytes (creatinine, alanine aminotransferase, alkaline phosphatase, total bilirubin) remained within ± 1 SD of baseline values. This finding is useful in situations where centrifuging blood samples might not be possible. For application to high-containment studies, we also evaluated the utility of data from plasma stored overnight at −20°C and γ-irradiated (5 × 106 rads) before analysis. Under these conditions, 6 of 12 analytes varied by >1 SD from expected range, suggesting that samples should be processed before inactivation by γ-irradiation. Finally, we assessed effects of storing reagent discs at room temperature or 32°C for varying lengths of time. Although discs must be refrigerated when stored >48 hours, all values obtained from discs stored at room temperature for a week were within ± 1 SD of controls, except glucose and γ-glutamyltransferase (± 1–2 SD). Data from discs stored at 32°C for 5 days were similarly comparable with baseline; we observed deviations in glucose, γ-glutamyltransferase, and creatinine. Discs stored at 32°C for 14 days were unreliable; many generated no values or a “disc error” message. However, values read from discs that did not result in an error message were all within expected limits. All discs stored at 32°C for 5 weeks generated error messages. These findings suggest that although extended storage at elevated temperatures substantially damages discs, discs stored at these conditions for up to 2 weeks might still yield clinically relevant data. In summary, we found that under various suboptimal conditions, many analytes are still readily comparable (within ± 1 SD of intrinsic variation) to those from paired samples handled according to the manufacturer’s recommendations. In addition, the pattern of values that deviate from baseline is often consistent (e.g., glucose decreases) and may be considered in clinical evaluation. Although we used SDs to highlight deviation here, the clinical implication of these findings will vary based on the analyte and condition being monitored. We believe these findings, based on guinea pig samples, enabling us to efficiently sample a large population and process under controlled conditions, are translatable to other species, including humans, because the equivalent veterinary point-of-care platform (VetScan VS2) is also disc-based and uses comparable assay chemistry. However, the possibility for some species differences remains and should be considered for future investigations.

Appendix

Results of clinical chemistry values obtained on the Piccolo Xpress Chemistry Analyzer from blood samples processed under various conditions.
  10 in total

1.  Analytical performance of the Abaxis Piccolo Xpress® point of care analyzer in whole blood, serum, and plasma.

Authors:  Kazunori Murata; Laurel Glaser; Mary Nardiello; Shaun Richardson; Lakshmi V Ramanathan; Dean C Carlow
Journal:  Clin Biochem       Date:  2015-08-06       Impact factor: 3.281

2.  Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study.

Authors:  Luke Hunt; Ankur Gupta-Wright; Victoria Simms; Fayia Tamba; Victoria Knott; Kongoneh Tamba; Saidu Heisenberg-Mansaray; Emmanuel Tamba; Alpha Sheriff; Sulaiman Conteh; Tom Smith; Shelagh Tobin; Tim Brooks; Catherine Houlihan; Rachael Cummings; Tom Fletcher
Journal:  Lancet Infect Dis       Date:  2015-08-10       Impact factor: 25.071

3.  Clinical Chemistry of Patients With Ebola in Monrovia, Liberia.

Authors:  Emmie de Wit; Shelby Kramer; Joseph Prescott; Kyle Rosenke; Darryl Falzarano; Andrea Marzi; Robert J Fischer; David Safronetz; Thomas Hoenen; Allison Groseth; Neeltje van Doremalen; Trenton Bushmaker; Kristin L McNally; Friederike Feldmann; Brandi N Williamson; Sonja M Best; Hideki Ebihara; Igor A C Damiani; Brett Adamson; Kathryn C Zoon; Tolbert G Nyenswah; Fatorma K Bolay; Moses Massaquoi; Armand Sprecher; Heinz Feldmann; Vincent J Munster
Journal:  J Infect Dis       Date:  2016-07-28       Impact factor: 5.226

4.  Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis.

Authors:  Steven B Bradfute; Paul E Swanson; Mark A Smith; Eizo Watanabe; Jonathan E McDunn; Richard S Hotchkiss; Sina Bavari
Journal:  J Immunol       Date:  2010-01-01       Impact factor: 5.422

5.  Hematology and Clinical Chemistry Reference Intervals for Inbred Strain 13/n Guinea Pigs (Cavia Porcellus ).

Authors:  Sarah C Genzer; Thanhthao Huynh; Joann D Coleman-Mccray; Jessica R Harmon; Stephen R Welch; Jessica R Spengler
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-04-22       Impact factor: 1.232

6.  Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.

Authors:  Thomas W Geisbert; Chad E Mire; Joan B Geisbert; Yee-Peng Chan; Krystle N Agans; Friederike Feldmann; Karla A Fenton; Zhongyu Zhu; Dimiter S Dimitrov; Dana P Scott; Katharine N Bossart; Heinz Feldmann; Christopher C Broder
Journal:  Sci Transl Med       Date:  2014-06-25       Impact factor: 17.956

7.  Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2015.

Authors:  Emmie de Wit; Kyle Rosenke; Robert J Fischer; Andrea Marzi; Joseph Prescott; Trenton Bushmaker; Neeltje van Doremalen; Shannon L Emery; Darryl Falzarano; Friederike Feldmann; Allison Groseth; Thomas Hoenen; Bonventure Juma; Kristin L McNally; Melvin Ochieng; Victor Omballa; Clayton O Onyango; Collins Owuor; Thomas Rowe; David Safronetz; Joshua Self; Brandi N Williamson; Galina Zemtsova; Allen Grolla; Gary Kobinger; Mark Rayfield; Ute Ströher; James E Strong; Sonja M Best; Hideki Ebihara; Kathryn C Zoon; Stuart T Nichol; Tolbert G Nyenswah; Fatorma K Bolay; Moses Massaquoi; Heinz Feldmann; Barry Fields
Journal:  J Infect Dis       Date:  2016-06-21       Impact factor: 5.226

8.  Development of a new vaccine for the prevention of Lassa fever.

Authors:  Thomas W Geisbert; Steven Jones; Elizabeth A Fritz; Amy C Shurtleff; Joan B Geisbert; Ryan Liebscher; Allen Grolla; Ute Ströher; Lisa Fernando; Kathleen M Daddario; Mary C Guttieri; Bianca R Mothé; Tom Larsen; Lisa E Hensley; Peter B Jahrling; Heinz Feldmann
Journal:  PLoS Med       Date:  2005-06-28       Impact factor: 11.069

9.  Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa.

Authors:  Sara Carazo Perez; Elin Folkesson; Xavier Anglaret; Abdoul-Habib Beavogui; Emmanuel Berbain; Alseny-Modet Camara; Evelyn Depoortere; Annabelle Lefevre; Piet Maes; Kristian Nødtvedt Malme; Jean-Marie Denis Malvy; Sien Ombelet; Geertrui Poelaert; Daouda Sissoko; Alexis Tounkara; Pierre Trbovic; Pascal Piguet; Annick Antierens
Journal:  PLoS Negl Trop Dis       Date:  2017-06-22

10.  Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Authors:  Daouda Sissoko; Cedric Laouenan; Elin Folkesson; Abdoul-Bing M'Lebing; Abdoul-Habib Beavogui; Sylvain Baize; Alseny-Modet Camara; Piet Maes; Susan Shepherd; Christine Danel; Sara Carazo; Mamoudou N Conde; Jean-Luc Gala; Géraldine Colin; Hélène Savini; Joseph Akoi Bore; Frederic Le Marcis; Fara Raymond Koundouno; Frédéric Petitjean; Marie-Claire Lamah; Sandra Diederich; Alexis Tounkara; Geertrui Poelart; Emmanuel Berbain; Jean-Michel Dindart; Sophie Duraffour; Annabelle Lefevre; Tamba Leno; Olivier Peyrouset; Léonid Irenge; N'Famara Bangoura; Romain Palich; Julia Hinzmann; Annette Kraus; Thierno Sadou Barry; Sakoba Berette; André Bongono; Mohamed Seto Camara; Valérie Chanfreau Munoz; Lanciné Doumbouya; Patient Mumbere Kighoma; Fara Roger Koundouno; Cécé Moriba Loua; Vincent Massala; Kinda Moumouni; Célia Provost; Nenefing Samake; Conde Sekou; Abdoulaye Soumah; Isabelle Arnould; Michel Saa Komano; Lina Gustin; Carlotta Berutto; Diarra Camara; Fodé Saydou Camara; Joliene Colpaert; Léontine Delamou; Lena Jansson; Etienne Kourouma; Maurice Loua; Kristian Malme; Emma Manfrin; André Maomou; Adele Milinouno; Sien Ombelet; Aboubacar Youla Sidiboun; Isabelle Verreckt; Pauline Yombouno; Anne Bocquin; Caroline Carbonnelle; Thierry Carmoi; Pierre Frange; Stéphane Mely; Vinh-Kim Nguyen; Delphine Pannetier; Anne-Marie Taburet; Jean-Marc Treluyer; Jacques Kolie; Raoul Moh; Minerva Cervantes Gonzalez; Eeva Kuisma; Britta Liedigk; Didier Ngabo; Martin Rudolf; Ruth Thom; Romy Kerber; Martin Gabriel; Antonino Di Caro; Roman Wölfel; Jamal Badir; Mostafa Bentahir; Yann Deccache; Catherine Dumont; Jean-François Durant; Karim El Bakkouri; Marie Gasasira Uwamahoro; Benjamin Smits; Nora Toufik; Stéphane Van Cauwenberghe; Khaled Ezzedine; Eric D'Ortenzio; Eric Dortenzio; Louis Pizarro; Aurélie Etienne; Jérémie Guedj; Alexandra Fizet; Eric Barte de Sainte Fare; Bernadette Murgue; Tuan Tran-Minh; Christophe Rapp; Pascal Piguet; Marc Poncin; Bertrand Draguez; Thierry Allaford Duverger; Solenne Barbe; Guillaume Baret; Isabelle Defourny; Miles Carroll; Hervé Raoul; Augustin Augier; Serge P Eholie; Yazdan Yazdanpanah; Claire Levy-Marchal; Annick Antierrens; Michel Van Herp; Stephan Günther; Xavier de Lamballerie; Sakoba Keïta; France Mentre; Xavier Anglaret; Denis Malvy
Journal:  PLoS Med       Date:  2016-03-01       Impact factor: 11.069

  10 in total
  1 in total

1.  Alterations in Blood Chemistry Levels Associated With Nipah Virus Disease in the Syrian Hamster Model.

Authors:  Sarah C Genzer; Stephen R Welch; Florine E M Scholte; Jessica R Harmon; JoAnn D Coleman-McCray; Michael K Lo; Joel M Montgomery; Stuart T Nichol; Christina F Spiropoulou; Jessica R Spengler
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.